Is Vijaya Diagnostic Centre the Best Stock in Its Sector? A Look at the Numbers
- October 15, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Vijaya Diagnostic Centre CMP Rs 1,402 (15 Oct 2026). Market cap Rs 14,443 Cr. ROE 18.07%. P/E 77.05x versus Industry P/E 61.23x.
Quick Answer
Vijaya Diagnostic Centre is one of the names investors compare when screening the Healthcare sector. Whether it is the best stock in its sector depends on whether an investor prioritises return ratios, valuation or balance sheet strength. This article sets it against two named peers and the sector benchmark so you can judge for yourself.
Is Vijaya Diagnostic Centre the best stock in its sector? The stock trades on the NSE at Rs 1,402 as of 15 October 2026, within its 52-week range of Rs 848.00 to Rs 1,593.60. The sections below cover the business, the key ratios, a peer comparison and a closer look at valuation.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Vijaya Diagnostic Centre
Vijaya Diagnostic Centre Ltd is a Hyderabad based diagnostics chain. It runs pathology labs and imaging centres, with a strong base in south India, and it has been expanding to more cities. At a market capitalisation of Rs 14,443 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Vijaya Diagnostic Centre the Best Stock in Its Sector?
Vijaya Diagnostic Centre’s case in the sector rests on return quality rather than cheap valuation, since the stock trades at a premium to its Industry P/E. Vijaya Diagnostic Centre’s 77.05x P/E is above the 61.23x Industry P/E, Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x, while its 18.07% ROE is lower than Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%, and its debt to equity ratio of 0.44 is above Dr Lal PathLabs at 0.08 and Thyrocare Technologies at 0.09.
| Metric | Vijaya Diagnostic Centre |
|---|---|
| CMP (NSE) | Rs 1,402.20 |
| 52-Week High / Low | Rs 1,593.60 / Rs 848.00 |
| Market Cap | Rs 14,443 Cr |
| P/E (TTM) vs Industry P/E | 77.05x vs 61.23x |
| P/B | 15.09 |
| ROE | 18.07% |
| EPS (TTM) | Rs 18.20 |
| Dividend Yield | 0.14% |
| Debt to Equity | 0.44 |
Compare Vijaya Diagnostic Centre Against Other Healthcare Sector Stocks
How Vijaya Diagnostic Centre Compares Against Its Healthcare Sector Peers
The table below sets Vijaya Diagnostic Centre against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Vijaya Diagnostic Centre | 14,443 | 77.05 | 18.07% | 0.44 |
| Dr Lal PathLabs | 32,511 | 59.51 | 20.13% | 0.08 |
| Thyrocare Technologies | 7,873 | 44.76 | 27.85% | 0.09 |
| Peer average (2 companies) | – | 52.13 | 23.99% | 0.08 |
Measured against the peer averages, Vijaya Diagnostic Centre’s P/E is 48 percent above the 52.13x average, and its ROE is 5.92 percentage points below the 23.99% average. An average of just two companies is a rough guide, so treat the gap as a pointer for further research and not as a verdict.
What Makes Vijaya Diagnostic Centre Worth Watching in Healthcare
- Scale: At Rs 14,443 Cr, its market capitalisation is larger than Thyrocare Technologies (Rs 7,873 Cr), though smaller than Dr Lal PathLabs (Rs 32,511 Cr), which is a useful reminder that the peers differ in size as well as in valuation.
- Sector drivers: Rising health awareness, more preventive testing and new centres help patient volumes.
- Key risk: A high multiple means investors expect steady expansion, so slower network growth or pricing pressure from larger rivals could weigh on the stock.
Vijaya Diagnostic Centre Valuation: Is It Justified?
At a P/B ratio of 15.09, the market pays about Rs 15.09 for every rupee of book value, and the EPS (TTM) of Rs 18.20 is the earnings base behind the P/E. The stock trades about 12 percent below its 52-week high and about 65 percent above its 52-week low. The dividend yield of 0.14% is a modest income component, so returns depend mainly on the share price. As with any single stock, investors should weigh these figures against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Oracle Financial Services Software the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Vijaya Diagnostic Centre and other Healthcare sector stocks.
How to Track Vijaya Diagnostic Centre Before You Invest
Before deciding whether Vijaya Diagnostic Centre deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Vijaya Diagnostic Centre to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Vijaya Diagnostic Centre gives investors a clear set of numbers to work with, from returns and valuation to leverage and peer standing. Whether it earns the label of best stock in Healthcare depends on how much weight you give each of them and on how the business executes from here. Because the stock trades above its sector benchmark, execution matters more than usual if the current valuation is to hold. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Vijaya Diagnostic Centre the best stock in its sector?
Ans. There is no single definitive answer, because the best stock in a sector depends on whether an investor is prioritising returns, valuation or balance sheet strength. Vijaya Diagnostic Centre has an 18.07% ROE and trades at 77.05x P/E against a 61.23x Industry P/E. Against the 2 peers compared in this article, its ROE is below the 23.99% peer average and its P/E is above the 52.13x peer average. Its debt to equity ratio of 0.44 is above the 0.08 peer average, which matters because borrowing can inflate returns and add risk when business conditions weaken. These figures are best read together rather than in isolation, and they work as a starting point for your own research and not as a verdict.
What is the current share price of Vijaya Diagnostic Centre?
Ans. Vijaya Diagnostic Centre was trading at Rs 1,402.20 on the NSE as of 15 October 2026, and its 52-week range runs from Rs 848.00 to Rs 1,593.60. That leaves the share price 12 percent short of the 52-week high and 65 percent clear of the 52-week low. Its market capitalisation is Rs 14,443 Cr and its EPS (TTM) is Rs 18.20, which is the earnings figure behind the 77.05x P/E. Share prices change through the trading day, so check the live quote on Univest before acting on any number here.
What sector does Vijaya Diagnostic Centre belong to?
Ans. Vijaya Diagnostic Centre is classified under the Healthcare sector on Univest, and that group of listed companies is the reference point for the 61.23x Industry P/E used in this article. The 2 named peers compared here are Dr Lal PathLabs and Thyrocare Technologies, chosen as comparable listed names so that the P/E, ROE and debt figures come from the same live data source. Investors who want a wider view can compare more Healthcare sector stocks on the Univest Screener, since no two companies in a sector have exactly the same business mix.
How does Vijaya Diagnostic Centre compare to its sector peers on P/E?
Ans. Vijaya Diagnostic Centre’s P/E of 77.05x is above the 52.13x average of the 2 named peers, with Dr Lal PathLabs at 59.51x and Thyrocare Technologies at 44.76x. It also sits above the 61.23x Industry P/E, which is the benchmark for the wider Healthcare sector. A P/E that is above a peer average can reflect a valuation discount or premium, but it can also reflect different growth or return expectations, so it should be read alongside ROE and debt. Its P/B ratio of 15.09 gives one more view of how the market values its book value.
What is Vijaya Diagnostic Centre’s return on equity?
Ans. Vijaya Diagnostic Centre reported a return on equity of 18.07%, which is below the 23.99% average of its named peers, with Dr Lal PathLabs at 20.13% and Thyrocare Technologies at 27.85%. ROE shows how much profit a company generates on every rupee of shareholders’ equity, so a higher figure generally points to more efficient use of capital. ROE is easier to trust when leverage is modest, and here the debt to equity ratio is 0.44 against a peer average of 0.08. It is worth checking whether the ROE has been stable over several years rather than relying on a single reading.
Should I invest in Vijaya Diagnostic Centre based on its sector position?
Ans. Sector position is only one input into an investment decision. Vijaya Diagnostic Centre has an 18.07% ROE and a 77.05x P/E, which make it worth researching further, and its dividend yield is 0.14%. You should also weigh its business outlook, earnings consistency, debt levels, your investment horizon and your own risk appetite before buying. Spreading money across several stocks and sectors reduces concentration risk, and this article is educational content, not investment advice. For personalised guidance, consult a SEBI-registered advisor.
